Gallant Therapeutics

Gallant Therapeutics is a clinical-stage animal health biotechnology company with a focus on revolutionizing the field of animal health through the use of stem cell therapy. The company's slogan "Setting a New Standard in Animal Health🐾" reflects its commitment to treating the root cause of diseases in dogs and cats by harnessing the power of stem cell therapy. Gallant Therapeutics aims to address a broad range of diseases, including canine and feline osteoarthritis and chronic kidney disease, using off-the-shelf mesenchymal stem cell (MSC) therapies.

Founded in 2018 and headquartered in the United States, Gallant Therapeutics has garnered attention for its innovative approach to veterinary regenerative medicine. The company's pipeline includes a breakthrough uterine-derived platform for feline chronic gingivostomatitis (FCGS), with the first product expected to receive conditional approval by the FDA in 2025.

The company's prowess in cell therapy product development, manufacturing, and commercialization is backed by a team of industry pioneers with a profound commitment to animal welfare. Gallant's recent Seed Round investment at 01 December 2022, led by Unpopular Ventures, highlights its potential to attract support from forward-thinking investors who recognize the significance of its groundbreaking approach in the field of biotechnology.